sábado, 7 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 22, 2026

The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell

View original at nasdaq.com
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell For Immediate Releases Chicago, IL – April 22, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shopify's expanding international footprint with strong growth in Europe is a key catalyst

    60% confidence
  • Goldman Sachs solid liquidity profile will support its capital distribution activities

    60% confidence
  • Landmark Bancorp presents a compelling regional banking story, supported by a diversified lending franchise across residential, commercial and agricultural segments

    60% confidence
  • Goldman Sachs expansion in the private equity credit market is expected to diversify its revenue base and support its growth over the long run

    60% confidence
  • NextEra Energy's robust renewable backlog indicates strong earnings in the long-term

    60% confidence
  • ImmuCell has a differentiated, market-leading product in calf scours prevention that continues to gain share due to its consistent efficacy versus traditional alternatives

    60% confidence
  • Shopify faces gross margin pressure due to higher hosting costs, the three-month paid trial program, and the expanded PayPal partnership, which carries lower margins

    60% confidence
  • Shopify's investment in AI-driven tools is helping merchants improve customer engagement and streamline operations

    60% confidence
  • Goldman Sachs high dependence on overseas revenues is worrisome

    60% confidence
  • Goldman Sachs is narrowing the consumer footprint and prioritizing durable revenue streams across banking, markets and alternatives

    60% confidence
  • Shopify's prospects are benefiting from an expanding merchant base

    60% confidence
  • Florida's improving economy is generating demand and boosting FPL's customer base

    60% confidence
  • Since 2000, top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    60% confidence
  • Goldman Sachs rising expense base might hamper the company's near-term profitability

    60% confidence
  • Goldman Sachs earnings beat estimates in each of the four trailing quarters

    60% confidence
  • Risks in operating nuclear power-based generation units, unfavorable weather conditions and increasing supply costs can adversely impact NextEra Energy earnings

    60% confidence
  • NextEra Energy will add more renewable projects to its portfolio and has nearly 29.8 GW of renewable projects in the backlog

    60% confidence

Data points we hold from this source

S&P 500 · average annual return7.7 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell — Source | Via News | es.VIA.NEWS